Annexon, Inc. (ANNX)
Fuera de horario:
Annexon, Inc.
1400 Sierra Point Parkway
Building C Suite 200
Brisbane, CA 94005
United States
650 822 5500
https://www.annexonbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 70
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Douglas Love Esq., J.D. | CEO, President & Director | 980.12k | N/D | 1968 |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP | 797.38k | N/D | 1961 |
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 697.76k | N/D | 1958 |
| Ms. Jennifer Lew | Executive VP, CFO & Corporate Secretary | 624.2k | N/D | 1973 |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer | 580.47k | N/D | 1971 |
| Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine | N/D | N/D | N/D |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer | N/D | N/D | 1958 |
Descripción
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Annexon, Inc. a partir del 1 de junio de 2024 es 7. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 8; Compensación: 9.
